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LETTERS TO THE EDITOR
Pulmonary
Pleomorphic
Carcinoma
Diagnosis Using Small
Biopsy Specimens
To the Editor:
We read with great interest the ar-
ticle by Kaira et al.,1 who reported a clin-
icopathological study of 17 cases of pul-
monary pleomorphic carcinoma (PPC)
including epidermal growth factor recep-
tor gene mutation analysis. A PPC is a rare
tumor, although a few previous studies
that investigated a sufficient number of
resected specimens showed that the prog-
nosis of affected patients is generally
poorer than that of patients with other
types of non-small cell lung cancer
(NSCLC).2,3
Among patients with primary lung
carcinomas who underwent surgery at
Osaka Prefectural Medical Center for
Respiratory and Allergic Diseases from
1980 through 2009, 18 (0.7%) under-
went resection of a PPC. Patients (17
men; 1 woman) with a PPC were be-
tween 32 and 83 years of age (mean 63
years). According to the 2009 tumor
node metastasis classification (UICC-7),
3 of those cases were stage I, 10 were
stage II, and 5 were stage III. Follow-up
of the 18 patients ranged from 1.6 to
140.9 (median 6.0) months and 12
(67%) died of recurrence during the fol-
low-up period. The median overall sur-
vival time was 7.1 (95% confidence in-
terval: 0.5–13.7) months. Using biopsy
specimens, none of these cases were
diagnosed preoperatively as PPC but
rather as poorly differentiated adenocar-
cinoma, large cell carcinoma, pulmo-
nary blastoma, or sarcoma.
In the study by Kaira et al.,1 only
nine patients (53%) were diagnosed as
PPC based on surgical resection results,
whereas seven patients were diagnosed
by bronchoscopic biopsy and one by
surgical biopsy findings. Although they
described the limitations of their study
in light of the pathologic specimens, we
would like to add the following com-
ments that focus on the diagnosis of
PPC using small biopsy specimens.
According to the 2004 World
Health Organization classification,4 a PPC
is defined as poorly differentiated NSCLC
containing spindle cells and/or giant cells
(sarcomatoid component) or a carcinoma
consisting only spindle and giant cells.
The sarcomatoid component should com-
prise at least 10% of the tumor. The pres-
ence of differentiated sarcomatous ele-
ments such as malignant cartilage, bone,
or skeletal muscle leads to diagnosis of a
malignant tumor with a mixture of NSCLC
and sarcoma as a carcinosarcoma. Further-
more, combined small cell carcinoma
should also be excluded. As noted above,
a thorough investigation of the whole tu-
mor is needed for a definitive diagnosis of
PPC; thus, because of sampling issues and
histologic heterogeneity, such diagnosis
requires a resected specimen, and it is im-
possible or at least inappropriate to make a
definitive diagnosis based on findings ob-
tained from small biopsy specimens.3–5
Even under the best of circumstances, a
tumor may be diagnosed as a primary or
metastatic non-small cell carcinoma with
pleomorphic features or an undifferentiated
spindle/giant cell neoplasm when using
small biopsy specimens.
We respectfully ask for the key to
a definitive diagnosis of PPC based on
small biopsy specimens. Such informa-
tion would be helpful for both diagnosis
and treatment of patients with an ad-
vanced unresectable PPC.
Teruo Iwasaki, MD, PhD
Mitsunori Ohta, MD, PhD
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Osaka Prefectural Medical Center for
Respiratory and Allergic Diseases
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In Response:
We thank Dr. Iwasaki for his in-
terest about our article. They described
that it is impossible or at least inappro-
priate to make a definitive diagnosis
based on finding obtained from small
biopsy. We also agree their suggestions.
In our study, seven patients were
diagnosed by transbronchial biopsy. This
is one of the limitations of our study. As
described in our article, however, only
patients with an adequate specimen ob-
tained during bronchoscopic biopsy were
eligible for our study. The definitive diag-
nosis of pulmonary pleomorphic carci-
noma (PPC) could be made with the help
of immunohistochemistry. The differential
diagnoses included poorly differentiated
primary squamous cell carcinoma and ad-
enocarcinoma, primary sarcoma, meta-
static poorly differentiated carcinomas,
and metastatic sarcoma. Recently, Zafar
and Johns1 described that immunohisto-
chemistry was helpful for the definitive
diagnosis of PPC. Previous report also
supports the usefulness of immunohis-
tochemical technique.2 Ito et al.3 also
retrospectively analyzed 22 PPC and
described that three patients were di-
agnosed by transbronchial biopsy
only. In their report, there had been no
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detailed information on the immuno-
histochemistry. However, we consider
that the using of immunohistochemical
technique is mandatory for the diagno-
sis of PPC.
In clinical practice, the diagnosis
using biopsy specimens is necessary for
patients with advanced unresectable PPC.
However, we also think that the definite
diagnosis of PPC could not be easily made
because of small biopsy specimens. In our
institution, we have some cases suspecting
PPC in the diagnosis using small biopsy
specimens and could not make the definite
diagnosis of PPC with the help of immu-
nohistochemistry. In this study, however,
seven patients had an adequate specimen
regardless of transbronchial biopsy, there-
fore, we believe that the definite diagnosis
of PPC could be made with the help of
immunohistochemistry.
Kyoichi Kaira, MD, PhD
Nobuyuki Yamamoto, MD, PhD
Division of Thoracic Oncology
Shizuoka Cancer Center, Sunto-gun
Shizuoka 411-8777, Japan
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